---
title: Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
date: '2024-08-30'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39213194/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240831181357&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Among patients with ATTR-CM, treatment with vutrisiran
  led to a lower risk of death from any cause and cardiovascular events than placebo
  and preserved functional capacity and quality of life. (Funded by Alnylam Pharmaceuticals;
  HELIOS-B ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Among patients with ATTR-CM, treatment with vutrisiran led to a lower risk of death from any cause and cardiovascular events than placebo and preserved functional capacity and quality of life. (Funded by Alnylam Pharmaceuticals; HELIOS-B ClinicalTrials.gov number, ...